Product Description — Tesamorelin

Product Name: Tesamorelin
Primary CAS Number: 218949-48-5.

Regulatory notice (must appear on product pages):
Prescription status: Rx (prescription drug) in the United States for a specified, approved indication. Do not market for unapproved uses. See full prescribing information for indications, contraindications, warnings, and dosing.
FDA Access Data
+1

Overview=

Tesamorelin is a stabilized analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to release growth hormone (GH) and thereby increases circulating insulin-like growth factor-1 (IGF-1). In the U.S., the marketed product EGRIFTA® (tesamorelin for injection) is FDA-approved for reducing excess abdominal fat (visceral adipose tissue) in adult patients with HIV-associated lipodystrophy — not for general cosmetic use or for indications beyond those in the approved label. All promotional or product pages should adhere to label language and avoid implying broader or unapproved therapeutic benefits.
NCBI
+1

Key FDA-load-bearing facts

Approved indication (U.S.): Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy — only as described in the prescribing information.

Important safety considerations: Tesamorelin increases IGF-1 and may affect glucose tolerance; monitor patients for hyperglycemia and other risks described in the label (including potential hypersensitivity). Review full prescribing information for contraindications, pregnancy warnings, and monitoring requirements.
FDA Access Data
+1

Regulation-Safe Product Description

Tesamorelin (CAS 218949-48-5)
Tesamorelin is a stabilized growth hormone-releasing hormone (GHRH) analogue indicated for the reduction of excess abdominal fat in adult patients with HIV-associated lipodystrophy (see full prescribing information). It acts by stimulating pituitary GH secretion, leading to increased IGF-1 concentrations. Tesamorelin is supplied and administered only under prescription and must be used in accordance with the approved label. Not for over-the-counter sale.

Important: This product may affect glucose metabolism and is associated with specific contraindications and warnings. Clinicians should consult the current EGRIFTA® prescribing information for dosing, monitoring, and safety details prior to use.
FDA Access Data
+1

Chemical / physical identifiers

CAS: 218949-48-5.
Wikipedia

PubChem CID: 16137828 (structural and identifier data).
PubChem

Empirical formula (as listed in reference sources): C₂₂₁H₃₆₆N₇₂O₆₇S (salts/variants indexed separately).
Wikipedia

Molecular weight: large peptide (reported in label and chemical databases). Refer to product specification sheet for the exact lot certificate.

“Indicated for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.”
FDA Access Data

“This product acts as a GHRH analogue and increases circulating IGF-1; review warnings for glucose intolerance and other risks.”
NCBI

Storage & handling (label-consistent summary)

Follow storage and handling instructions in the approved prescribing information and product packaging. For EGRIFTA® formulations, see the label for reconstitution, storage temperature, and administration guidance.
FDA Access Data
+1

SEO / informational keywords (use carefully; avoid implying unapproved benefits)

Use these informational keywords on medical or product pages and meta tags (avoid consumer-directed health claims in meta/descriptions):

tesamorelin information

Egrifta prescribing information

tesamorelin CAS 218949-48-5

Falutz J, et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat — pivotal clinical studies (J Clin Endocrinol Metab).
OUP Academic

LiverTox / NCBI summary on Tesamorelin (mechanism and hepatic considerations).
NCBI

Recent post-hoc and clinical analyses of tesamorelin efficacy and safety in people with HIV.
PMC